Personalized heart risk assessment for cancer survivors
Treatments studied
Part of Cancer, Heart & circulation, Hormones & metabolism, Injuries & trauma clinical trials.
This study tests a new tool that helps doctors figure out your risk for heart problems after cancer treatment. If you join, you'll get a heart risk check and possibly see a heart specialist. This could help prevent heart issues later.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 years or older and have had cancer.
- You have not seen a heart doctor for a heart risk check since your cancer diagnosis.
- You do not have cardiomyopathy (a weakened heart muscle) that was found after your cancer diagnosis.
- You are able to understand and sign a consent form.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests whether a personalized, risk-based heart care plan can help prevent heart failure in people who had certain cancer treatments. It focuses on monitoring and guiding treatment, using heart ultrasound results and other health factors.
This trial tests whether a “risk-guided” care plan can help prevent coronary artery disease (the buildup that can lead to heart attacks) in people who had cancer treatment that can affect the heart. You may get closer heart risk monitoring and guidance to reduce risk factors, such as cholesterol—especially if you can safely take statins.
This study tests a structured heart rehabilitation program for people who have had cancer treatment. It aims to improve heart health and reduce cardiovascular problems in cancer survivors.
This study is a “registry,” meaning it collects health information from adults who are getting a new heart (cardio) evaluation related to cancer. It helps doctors better understand heart risks and care needs for different cancer types and treatments.
This trial uses a special scoring system (ML Score) to predict if you might develop heart problems while receiving anthracycline chemotherapy or HER2-targeted therapies. It helps doctors decide on the best heart monitoring plan before starting treatment.
This study is testing a new way to assess heart and blood vessel risk specifically for women aged 40 to 65. It will help doctors better understand your personal risk and may lead to earlier prevention measures.
Hear when a new Heart failure trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.